115 related articles for article (PubMed ID: 3145318)
1. Effect of LHRH agonist (buserelin) on pulsatile secretion of LHRH and LH.
Okuda K; Ushiroyama T; Yoshikawa M; Sugimoto O
Nihon Sanka Fujinka Gakkai Zasshi; 1988 Dec; 40(12):1889-93. PubMed ID: 3145318
[TBL] [Abstract][Full Text] [Related]
2. Reversible pituitary ovarian suppression induced by an LHRH agonist in the treatment of endometriosis--comparison of two dose regimens.
Shaw RW; Matta W
Clin Reprod Fertil; 1986 Oct; 4(5):329-36. PubMed ID: 3100012
[TBL] [Abstract][Full Text] [Related]
3. Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis.
Lemay A; Maheux R; Faure N; Jean C; Fazekas AT
Fertil Steril; 1984 Jun; 41(6):863-71. PubMed ID: 6427019
[TBL] [Abstract][Full Text] [Related]
4. [Androgens and other hormones in buserelin therapy].
Fuchs U; Zwirner M
Geburtshilfe Frauenheilkd; 1991 Feb; 51(2):140-2. PubMed ID: 1904040
[TBL] [Abstract][Full Text] [Related]
5. Chronic treatment with the gonadotropin-releasing hormone agonist D-Ser(TBU)6-EA10-LRH for contraception in women and men.
Nillius SJ; Bergquist C; Wide L
Int J Fertil; 1980; 25(3):239-46. PubMed ID: 6108935
[TBL] [Abstract][Full Text] [Related]
6. [Continuous subcutaneous infusion of GnRH agonist: effective dosage in the treatment of endometriosis and its influence on the ovarian response to human menopausal gonadotropin].
Masaoka K; Kitazawa M; Watanabe H; Kumasaka T
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jun; 41(6):729-36. PubMed ID: 2504848
[TBL] [Abstract][Full Text] [Related]
7. Clinical study on finding optimal dose of a potent LHRH agonist (buserelin) for the treatment of endometriosis--multicenter trial in Japan.
Minaguchi H; Uemura T; Shirasu K
Prog Clin Biol Res; 1986; 225():211-25. PubMed ID: 3097667
[No Abstract] [Full Text] [Related]
8. Effect of RU486 injected on proestrous morning on LHRH, LH and 17beta-estradiol secretion during the estrous cycle in rat.
Tébar M; Ruiz A; González D; Hernández G; Alonso R; Sánchez-Criado JE
J Physiol Biochem; 1998 Jun; 54(2):91-7. PubMed ID: 9858129
[TBL] [Abstract][Full Text] [Related]
9. CA-125 monitored therapy with GnRH analogue of pelvic endometriosis.
Negri P; Ricciardelli MA; Tomasi A; Grechi E; Fortini RM
Acta Eur Fertil; 1992; 23(4):171-4. PubMed ID: 1343472
[TBL] [Abstract][Full Text] [Related]
10. [Initial results in the treatment of endometriosis with the LH-RH analog buserelin].
Hardt W; Schmidt-Gollwitzer M; Schmidt-Gollwitzer K; Genz T; Nevinny-Stickel J
Geburtshilfe Frauenheilkd; 1986 Aug; 46(8):483-9. PubMed ID: 3093311
[TBL] [Abstract][Full Text] [Related]
11. Pulsatile luteinizing hormone releasing hormone treatment for induction of ovulation. Radioimmunoassay of plasma LHRH and comparative study of subcutaneous versus intravenous routes of administration.
Couzinet B; Lahlou N; Lestrat N; Bouchard P; Roger M; Schaison G
J Endocrinol Invest; 1986 Apr; 9(2):103-8. PubMed ID: 3519743
[TBL] [Abstract][Full Text] [Related]
12. [Successful treatment of endometriosis in women with continuous subcutaneous infusion of gonadotropin-releasing hormone agonist (GnRH-A)].
Masaoka K; Kitazawa M; Kumasaka T
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Apr; 41(4):405-11. PubMed ID: 2501437
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis.
Lemay A; Maheux R; Huot C; Blanchet J; Faure N
Am J Obstet Gynecol; 1988 Feb; 158(2):233-6. PubMed ID: 3124618
[TBL] [Abstract][Full Text] [Related]
14. Potential new treatment of endometriosis: reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LH-RH) agonist.
Lemay A; Quesnel G
Fertil Steril; 1982 Sep; 38(3):376-9. PubMed ID: 6214431
[TBL] [Abstract][Full Text] [Related]
15. Luteinizing hormone releasing hormone agonist for contraception in breast feeding women.
Fraser HM; Dewart PJ; Smith SK; Cowen GM; Sandow J; McNeilly AS
J Clin Endocrinol Metab; 1989 Nov; 69(5):996-1002. PubMed ID: 2507572
[TBL] [Abstract][Full Text] [Related]
16. Influence of the gonad on the degree of suppression induced by an LHRH agonist implant in the marmoset monkey.
Lunn SF; Cowen GM; Morris KD; Fraser HM
J Endocrinol; 1992 Feb; 132(2):217-24. PubMed ID: 1541921
[TBL] [Abstract][Full Text] [Related]
17. [Episode secretion of LH releasing hormone and LH in peripheral plasma of women with and without ovulatory disturbances].
Okuda K; Yata M; Yoshikawa M; Ishida M; Miyazaki K; Sugimoto O
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Dec; 37(12):2799-805. PubMed ID: 3910741
[TBL] [Abstract][Full Text] [Related]
18. Serum concentration and urinary excretion of the luteinizing hormone-releasing hormone agonist buserelin in patients with endometriosis.
Kiesel L; Sandow J; Bertges K; Jerabek-Sandow G; Trabant H; Runnebaum B
J Clin Endocrinol Metab; 1989 Jun; 68(6):1167-73. PubMed ID: 2498387
[TBL] [Abstract][Full Text] [Related]
19. Failure of positive feedback of oestradiol during chronic intranasal luteinizing hormone-releasing hormone agonist treatment.
Bergquist C; Nillius SJ; Wide L
Clin Endocrinol (Oxf); 1982 Feb; 16(2):147-51. PubMed ID: 6802530
[TBL] [Abstract][Full Text] [Related]
20. Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study.
Dmowski WP; Radwanska E; Binor Z; Tummon I; Pepping P
Fertil Steril; 1989 Mar; 51(3):395-400. PubMed ID: 2493400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
